Hikma Pharmaceuticals Plc (HKMPF) Stock Rating Reaffirmed by Morgan Stanley
Morgan Stanley reaffirmed their equal weight rating on shares of Hikma Pharmaceuticals Plc (OTC:HKMPF) in a research note issued to investors on Wednesday, MarketBeat reports.
A number of other brokerages also recently issued reports on HKMPF. Numis Securities Ltd reissued an add rating on shares of Hikma Pharmaceuticals Plc in a research report on Friday, May 19th. Jefferies Group LLC downgraded Hikma Pharmaceuticals Plc from a buy rating to an underperform rating in a research report on Wednesday, May 17th. Finally, ValuEngine raised Hikma Pharmaceuticals Plc from a hold rating to a buy rating in a research report on Thursday, July 27th. Two research analysts have rated the stock with a sell rating, three have given a hold rating and one has issued a buy rating to the stock. The company presently has a consensus rating of Hold and an average price target of $27.00.
Hikma Pharmaceuticals Plc (OTC HKMPF) remained flat at $18.60 during trading on Wednesday. The company has a 50 day moving average of $20.32 and a 200-day moving average of $23.55. The company has a market cap of $4.48 billion and a PE ratio of 28.10. Hikma Pharmaceuticals Plc has a 52 week low of $18.15 and a 52 week high of $29.75.
Receive News & Stock Ratings for Hikma Pharmaceuticals Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals Plc and related stocks with our FREE daily email newsletter.